Deal Watch: AzurRx Expands GI Pipeline With Buyout Of Partner First Wave

Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.

Deal Watch 2021

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

AzurRx BioPharma, Inc. agreed to buy out its partner, privately held First Wave Bio, Inc., on 13 September...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deal Watch

More from Deals